Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Increased by Truist Financial Corp

Truist Financial Corp grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 3.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 256,292 shares of the medical equipment provider's stock after acquiring an additional 8,200 shares during the quarter. Truist Financial Corp owned about 0.07% of Intuitive Surgical worth $126,934,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AlphaCore Capital LLC boosted its stake in Intuitive Surgical by 4.2% during the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after buying an additional 18 shares during the last quarter. Accredited Investors Inc. lifted its stake in shares of Intuitive Surgical by 1.9% in the 4th quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after purchasing an additional 19 shares during the last quarter. Second Line Capital LLC lifted its stake in shares of Intuitive Surgical by 3.4% in the 4th quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after purchasing an additional 19 shares during the last quarter. Colonial Trust Co SC lifted its stake in shares of Intuitive Surgical by 8.8% in the 4th quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock valued at $128,000 after purchasing an additional 20 shares during the last quarter. Finally, Crown Wealth Group LLC lifted its stake in shares of Intuitive Surgical by 4.8% in the 1st quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock valued at $218,000 after purchasing an additional 20 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

Intuitive Surgical stock traded down $10.54 during mid-day trading on Monday, reaching $533.93. 670,069 shares of the company were exchanged, compared to its average volume of 1,668,814. Intuitive Surgical, Inc. has a twelve month low of $413.82 and a twelve month high of $616.00. The firm's 50-day simple moving average is $537.11 and its two-hundred day simple moving average is $536.92. The firm has a market cap of $191.37 billion, a PE ratio of 78.29, a price-to-earnings-growth ratio of 5.78 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.71 by $0.10. The business had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same period last year, the firm earned $1.50 EPS. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ISRG. Robert W. Baird decreased their price target on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Erste Group Bank raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. Barclays decreased their target price on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Truist Financial decreased their target price on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their price target for the company from $515.00 to $440.00 in a research report on Monday, June 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $588.95.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Jami K. Nachtsheim sold 2,400 shares of the business's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the completion of the sale, the director owned 6,371 shares of the company's stock, valued at approximately $3,312,920. The trade was a 27.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the business's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the transaction, the senior vice president owned 907 shares in the company, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,998 shares of company stock worth $2,611,577 in the last three months. Company insiders own 0.70% of the company's stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.